Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort
Overview
Authors
Affiliations
Purpose: Understanding risk factors for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is important for optimizing patient care. We re-analyzed data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study (NCT00292552) to identify factors predictive of re-exacerbations and associated with prolonged AECOPDs.
Methods: Patients with COPD from ECLIPSE with moderate/severe AECOPDs were included. The end of the first exacerbation was the index date. Timing of re-exacerbation risk was assessed in patients with 180 days' post-index-date follow-up data. Factors predictive of early (1-90 days) vs late (91-180 days) vs no re-exacerbation were identified using a multivariable partial-proportional-odds-predictive model. Explanatory logistic-regression modeling identified factors associated with prolonged AECOPDs.
Results: Of the 1,554 eligible patients from ECLIPSE, 1,420 had 180 days' follow-up data: more patients experienced early (30.9%) than late (18.7%) re-exacerbations; 50.4% had no re-exacerbation within 180 days. Lower post-bronchodilator FEV (=0.0019), a higher number of moderate/severe exacerbations on/before index date (<0.0001), higher St. George's Respiratory Questionnaire total score (=0.0036), and season of index exacerbation (autumn vs winter, =0.00164) were identified as predictors of early (vs late/none) re-exacerbation risk within 180 days. Similarly, these were all predictors of any (vs none) re-exacerbation risk within 180 days. Median moderate/severe AECOPD duration was 12 days; 22.7% of patients experienced a prolonged AECOPD. The odds of experiencing a prolonged AECOPD were greater for severe vs moderate AECOPDs (adjusted odds ratio=1.917, =0.002) and lower for spring vs winter AECOPDs (adjusted odds ratio=0.578, =0.017).
Conclusion: Prior exacerbation history, reduced lung function, poorer respiratory-related quality-of-life (greater disease burden), and season may help identify patients who will re-exacerbate within 90 days of an AECOPD. Severe AECOPDs and winter AECOPDs are likely to be prolonged and may require close monitoring.
Esendagli D, Kokturk N, Baha A, Yapar D, Ozkan S, Sen E BMC Pulm Med. 2024; 24(1):590.
PMID: 39609669 PMC: 11605944. DOI: 10.1186/s12890-024-03399-7.
Chai A, Csoma B, Lazar Z, Bentley A, Bikov A J Clin Med. 2024; 13(18).
PMID: 39337111 PMC: 11433445. DOI: 10.3390/jcm13185624.
Liu C, Zhu J, Zhao L, Li G, Sun J, Zhang S Biomark Med. 2024; 18(10-12):513-521.
PMID: 39136445 PMC: 11364060. DOI: 10.1080/17520363.2024.2347199.
Heerema J, Hug S, Bear N, Hill K Chron Respir Dis. 2023; 20:14799731231211852.
PMID: 37934787 PMC: 10631319. DOI: 10.1177/14799731231211852.
Smoking cessation and vaccination.
Montes de Oca M, Laucho-Contreras M Eur Respir Rev. 2023; 32(167).
PMID: 36948500 PMC: 10032588. DOI: 10.1183/16000617.0187-2022.